Skip to main content
Top
Published in: BMC Medical Genetics 1/2019

Open Access 01-12-2019 | Coronary Heart Disease | Research article

Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study

Authors: Qian Zhuang, Chong Shen, Yanchun Chen, Xianghai Zhao, Pengfei Wei, Junxiang Sun, Yanni Ji, Xiaotian Chen, Song Yang

Published in: BMC Medical Genetics | Issue 1/2019

Login to get access

Abstract

Objectives

Whether high sensitivity C-reactive protein (hs-CRP) has a causal effect on coronary heart disease (CHD) is unclear. This study investigated the causal effect of hs-CRP on CHD risk using Mendelian Randomization (MR) analysis.

Methods

A total of 3802 subjects were recruited in the follow-up study. Linear regression model was used to evaluate the relationship between CRP polymorphisms and hs-CRP. Survival receiver operator characteristic curve method was used to explore the cut-off of hs-CRP on CHD incidence. Cox regression model was applied to detect the association of hs-CRP with CHD by calculating the hazard ratio (HR) and 95% confidence interval (CI). Rs1205 and rs876537 in CRP were selected as instrumental variables in MR analysis.

Results

During a median follow-up time of 5.01 years, 98 CHD incidence was identified (47.03/104 person-years). Hs-CRP was significantly increased among rs1205 and rs876537 genotypes with r values of 0.064 and 0.066, respectively. Hs-CRP 1.08 mg/L was identified as the cut-off value with a maximum value of sensitivity and specificity on prediction of CHD. Participants with ≥1.08 mg/L of hs-CRP has a higher risk of CHD incidence than that of participants with < 1.08 mg/L, the adjusted HR (95% CI) was 1.69 (1.11–2.60) with a P value of 0.016. No significant casual association was observed between hs-CRP and CHD with a P value of 0.777.

Conclusions

The association between hs-CRP and CHD is unlikely to be causal, hs-CRP might be a predictor for incidence of CHD in general population.
Appendix
Available only for authorised users
Literature
1.
go back to reference He J, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34.CrossRef He J, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34.CrossRef
2.
go back to reference Ripatti S, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376(9750):1393–400.CrossRef Ripatti S, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376(9750):1393–400.CrossRef
3.
go back to reference Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–26.CrossRef Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–26.CrossRef
4.
go back to reference Buckley DI, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 2009;151(7):483–95.CrossRef Buckley DI, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 2009;151(7):483–95.CrossRef
5.
go back to reference Mirhafez SR, et al. Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects. Eur J Clin Nutr. 2016;70(11):1298–304.CrossRef Mirhafez SR, et al. Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects. Eur J Clin Nutr. 2016;70(11):1298–304.CrossRef
6.
go back to reference Sugiyama T, et al. Relationship between serum high-sensitivity C-reactive protein and myocardial infarction in a general Japanese population. J Clin Lab Anal. 2016;30(6):999–1002.CrossRef Sugiyama T, et al. Relationship between serum high-sensitivity C-reactive protein and myocardial infarction in a general Japanese population. J Clin Lab Anal. 2016;30(6):999–1002.CrossRef
7.
go back to reference Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.CrossRef Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.CrossRef
8.
go back to reference Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol. 2008;4(5):234–5.CrossRef Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol. 2008;4(5):234–5.CrossRef
9.
go back to reference Zacho J, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897–908.CrossRef Zacho J, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897–908.CrossRef
10.
go back to reference Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44(2):512–25.CrossRef Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44(2):512–25.CrossRef
11.
go back to reference Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.CrossRef Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.CrossRef
12.
go back to reference Hartwig FP, et al. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45(6):1717–26.CrossRef Hartwig FP, et al. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45(6):1717–26.CrossRef
13.
go back to reference Collaboration, C.R.P.C.H.D.G, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.CrossRef Collaboration, C.R.P.C.H.D.G, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.CrossRef
14.
go back to reference Swerdlow DI, et al. HMG-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–61.CrossRef Swerdlow DI, et al. HMG-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–61.CrossRef
15.
go back to reference Chen J, et al. Common variants in TGFBR2 and miR-518 genes are associated with hypertension in the Chinese population. Am J Hypertens. 2014;27(10):1268–76.CrossRef Chen J, et al. Common variants in TGFBR2 and miR-518 genes are associated with hypertension in the Chinese population. Am J Hypertens. 2014;27(10):1268–76.CrossRef
16.
go back to reference Ridker PM. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J. 2004;2(4 Suppl 1):4–9.PubMed Ridker PM. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J. 2004;2(4 Suppl 1):4–9.PubMed
17.
go back to reference Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.CrossRef Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.CrossRef
18.
go back to reference Tracy RP, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol. 1997;17(6):1121–7.CrossRef Tracy RP, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol. 1997;17(6):1121–7.CrossRef
19.
go back to reference Burke AP, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105(17):2019–23.CrossRef Burke AP, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105(17):2019–23.CrossRef
20.
go back to reference Kawashiri MA, et al. Mendelian randomization: its impact on cardiovascular disease. J Cardiol. 2018;72(4):307–13.CrossRef Kawashiri MA, et al. Mendelian randomization: its impact on cardiovascular disease. J Cardiol. 2018;72(4):307–13.CrossRef
21.
go back to reference Elliott P, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302(1):37–48.CrossRef Elliott P, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302(1):37–48.CrossRef
Metadata
Title
Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study
Authors
Qian Zhuang
Chong Shen
Yanchun Chen
Xianghai Zhao
Pengfei Wei
Junxiang Sun
Yanni Ji
Xiaotian Chen
Song Yang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2019
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-019-0910-z

Other articles of this Issue 1/2019

BMC Medical Genetics 1/2019 Go to the issue